Your session is about to expire
← Back to Search
Stem Cell Therapy for Heart Failure (HECTOR Trial)
HECTOR Trial Summary
This trial will use a new cell therapy (hESC-CMs) to see if it can improve survival and heart function in patients who have chronic left ventricular dysfunction due to MI.
HECTOR Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowHECTOR Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.HECTOR Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a health condition that may limit my life to less than a year.I have a serious heart rhythm problem without a pacemaker or defibrillator.I have experienced rejection of a transplanted organ or cells.I need or am eligible for a procedure to improve blood flow to my heart.My blood tests show low levels of hematocrit, white cells, or platelets without a known cause.You have had an AICD (implantable defibrillator) activation within the last 60 days before joining the study.I have received an organ transplant.My heart's pumping ability is reduced.My heart has a narrowed aortic valve of 1.5 cm2 or less.You have tested positive for HIV, hepatitis B, or hepatitis C in your blood.You have a prosthetic aortic valve or a heart constriction device.Your kidneys are not filtering blood well, and the rate is less than 35 ml per minute per 1.73 square meters of body surface area.My heart valve condition is moderate to severe, confirmed by an echo test.My blood does not clot properly, and it's not because I'm taking Coumadin.I have been on stable heart failure medication for the required time.I was hospitalized recently or have high NT pro-BNP levels.My liver enzymes are more than three times the normal limit.I have been cancer-free for 5 years, except for certain skin or cervical cancers.I am on long-term medication to suppress my immune system.I have heart issues due to a past heart attack, confirmed by an imaging study.I am scheduled for a heart catheterization procedure within 5 to 10 weeks.I have experienced moderate to severe heart failure symptoms in the last 6 months.You have a device called an automated implantable cardioverter-defibrillator (AICD) implanted in your body.I am pregnant, nursing, or could become pregnant and am not using birth control.I am between 21 and 79 years old.You are allergic to penicillin or streptomycin.You have a serious allergy to contrast dye used in imaging tests.You have tested positive for COVID-19 in the last 30 days.I have experienced moderate to severe heart failure symptoms in the last 6 months.
- Group 1: Cohort 2
- Group 2: Cohort 3
- Group 3: Cohort 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does the eligibility criteria of this clinical experiment extend to individuals aged 70 and above?
"Participants must fall within the 21-80 age range to be eligible for this clinical trial. Simultaneously, 35 and 410 trials are available respectively for those under 18 or over 65 years old."
Is the recruitment stage of this study still open?
"Affirmative. As per the information listed on clinicaltrials.gov, this research endeavour is actively seeking participants. It was first published in March 22nd 2022 and has since been amended as of September 15th 2022; 18 individuals are required from a single medical site for completion."
Has the FDA sanctioned Cohort 3 for use in medical treatments?
"An assessment of Cohort 3's safety has been rated 1 due to the scarcity of evidence supporting its efficacy and security as this is an initial phase trial."
How many subjects are eligible for inclusion in this clinical trial?
"Affirmative. According to clinicaltrials.gov, this trial is still recruiting participants. Published initially on March 22nd 2022 and modified most recently on September 15th 2022, this research requires 18 volunteers from a single medical centre."
Who fulfills the criteria necessary to partake in this research?
"The ischemia trial has an age restriction of 21 to 80 and requires 18 volunteers. Those wishing to enrol must meet these requirements in order to be accepted."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Average response time
- < 2 Days
Most responsive sites:
- Stanford Hospital and Clinics: < 48 hours
Share this study with friends
Copy Link
Messenger